Template:Risk of breast cancer with menopausal hormone therapy in large observational studies
| Study | Therapy | Hazard ratio (95% CI) |
|---|---|---|
| E3N-EPIC: Fournier et al. (2005) | Estrogen alone | 1.1 (0.8–1.6) |
| Estrogen plus progesterone Transdermal estrogen Oral estrogen |
0.9 (0.7–1.2) 0.9 (0.7–1.2) No events | |
| Estrogen plus progestin Transdermal estrogen Oral estrogen |
1.4 (1.2–1.7) 1.4 (1.2–1.7) 1.5 (1.1–1.9) | |
| E3N-EPIC: Fournier et al. (2008) | Oral estrogen alone | 1.32 (0.76–2.29) |
| Oral estrogen plus progestogen Progesterone Dydrogesterone Medrogestone Chlormadinone acetate Cyproterone acetate Promegestone Nomegestrol acetate Norethisterone acetate Medroxyprogesterone acetate |
Not analyzeda 0.77 (0.36–1.62) 2.74 (1.42–5.29) 2.02 (1.00–4.06) 2.57 (1.81–3.65) 1.62 (0.94–2.82) 1.10 (0.55–2.21) 2.11 (1.56–2.86) 1.48 (1.02–2.16) | |
| Transdermal estrogen alone | 1.28 (0.98–1.69) | |
| Transdermal estrogen plus progestogen Progesterone Dydrogesterone Medrogestone Chlormadinone acetate Cyproterone acetate Promegestone Nomegestrol acetate Norethisterone acetate Medroxyprogesterone acetate |
1.08 (0.89–1.31) 1.18 (0.95–1.48) 2.03 (1.39–2.97) 1.48 (1.05–2.09) Not analyzeda 1.52 (1.19–1.96) 1.60 (1.28–2.01) Not analyzeda Not analyzeda | |
| E3N-EPIC: Fournier et al. (2014) | Estrogen alone | 1.17 (0.99–1.38) |
| Estrogen plus progesterone or dydrogesterone | 1.22 (1.11–1.35) | |
| Estrogen plus progestin | 1.87 (1.71–2.04) | |
| CECILE: Cordina-Duverger et al. (2013) | Estrogen alone | 1.19 (0.69–2.04) |
| Estrogen plus progestogen Progesterone Progestins Progesterone derivatives Testosterone derivatives |
1.33 (0.92–1.92) 0.80 (0.44–1.43) 1.72 (1.11–2.65) 1.57 (0.99–2.49) 3.35 (1.07–10.4) | |
| Footnotes: a = Not analyzed, fewer than 5 cases. Sources: Main: [1] Additional: [2][3][4][5] | ||
Template documentationSee also
References
- ^ Mirkin S (August 2018). "Evidence on the use of progesterone in menopausal hormone therapy". Climacteric. 21 (4): 346–354. doi:10.1080/13697137.2018.1455657. PMID 29630427. S2CID 4760386.
- ^ Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (April 2005). "Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort". Int. J. Cancer. 114 (3): 448–54. doi:10.1002/ijc.20710. PMID 15551359. S2CID 18697141.
- ^ Fournier A, Berrino F, Clavel-Chapelon F (January 2008). "Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study". Breast Cancer Res. Treat. 107 (1): 103–11. doi:10.1007/s10549-007-9523-x. PMC 2211383. PMID 17333341.
- ^ Fournier A, Mesrine S, Dossus L, Boutron-Ruault MC, Clavel-Chapelon F, Chabbert-Buffet N (June 2014). "Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort". Breast Cancer Res. Treat. 145 (2): 535–43. doi:10.1007/s10549-014-2934-6. PMC 5924370. PMID 24781971.
- ^ Cordina-Duverger E, Truong T, Anger A, Sanchez M, Arveux P, Kerbrat P, Guénel P (2013). "Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France". PLOS ONE. 8 (11): e78016. Bibcode:2013PLoSO...878016C. doi:10.1371/journal.pone.0078016. PMC 3815310. PMID 24223752.